Toronto, Ontario–(Newsfile Corp. – June 21, 2024) – Safe Supply Streaming Co Ltd. (CSE: SPLY) (FSE: QM4) (OTCQB: SSPLF) (“Safe Supply” or “the Company”) announces today that Frank Salvati has resigned from the Company’s Board of Directors, effective immediately.
The Board is considering the Company’s options with respect to the future composition of the Board and will issue a further news release if and when a replacement is identified.
Bill Panagiotakopoulos, CEO of Safe Supply, commented: “The Company would like to thank Frank for lending his time and expertise to executing Safe Supply’s strategies. We continue to look to review investments in emerging tech and medical testing companies and press forward in addressing current healthcare challenges.”
About Safe Supply Streaming Corp
Safe Supply Streaming Corp. (CSE: SPLY) is a publicly traded company focused on innovative healthcare solutions, including safe supply methodologies, medical testing, and AI-powered technology. The Company is dedicated to improving mental health and addiction treatment through cutting-edge advancements and strategic partnerships.
Investor Relations Contact:
Safe Supply Streaming Corp.
Email: info@safesupply.com
Phone: (123) 456-7890
Bill Panagiotakopoulos
Chief Executive Officer and Director
bill@safesupply.com
Website: www.safesupply.com
Forward-Looking Information and Statements
This press release contains forward-looking statements. All statements, other than statements of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/214023
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…